Catalent to ramp up J&J vaccine production at Italian plant
- The line, added as part of an expanded partnership with J&J, is expected to be operational in the fourth quarter, Catalent said.
- The move will help address some of the concerns regarding J&J's ability to meet vaccine supply goals in Europe.
Contract manufacturer Catalent said on Wednesday it was scaling up manufacturing capacity for Johnson & Johnson's COVID-19 vaccine at its Italian plant by adding a new vial-filling line.
The line, added as part of an expanded partnership with J&J, is expected to be operational in the fourth quarter, Catalent said.
Catalent's Bloomington, Indiana facility currently provides manufacturing and packaging services for J&J's vaccine in the United States.
The move will help address some of the concerns regarding J&J's ability to meet vaccine supply goals in Europe.
A European Union official told Reuters in March that J&J had flagged possible supply issues, which could affect its plans to deliver 55 million vaccine doses to the bloc in the second quarter of the year.